Predictive molecular pathology in the time of coronavirus disease (COVID-19) in Europe
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ..
AIMS: Lung cancer predictive biomarker testing is essential to select advanced-stage patients for targeted treatments and should be carried out without delays even during health emergencies, such as the coronavirus (COVID-19) outbreak.
METHODS: Fifteen molecular laboratories from seven different European countries compared 4 weeks of national lockdown to a corresponding period in 2019, in terms of tissue and/or plasma-based molecular test workload, analytical platforms adopted, number of cases undergoing programmed death-ligand1 (PD-L1) expression assessment and DNA-based molecular tests turnaround time.
RESULTS: In most laboratories (80.0%), tissue-based molecular test workload was reduced. In 40.0% of laboratories (6/15), the decrease was >25%, and in one, reduction was as high as 80.0%. In this instance, a concomitant increase in liquid biopsy was reported (60.0%). Remarkably, in 33.3% of the laboratories, real-time PCR (RT-PCR)-based methodologies increased, whereas highly multiplexing assays approaches decreased. Most laboratories (88.9%) did not report significant variations in PD-L1 volume testing.
CONCLUSIONS: The workload of molecular testing for patients with advanced-stage lung cancer during the lockdown showed little variations. Local strategies to overcome health emergency-related issues included the preference for RT-PCR tissue-based testing methodologies and, occasionally, for liquid biopsy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2020 |
|---|---|
| Enthalten in: |
Journal of clinical pathology - (2020) vom: 31. Juli |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Malapelle, Umberto [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Revised 27.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1136/jclinpath-2020-206957 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM313126712 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM313126712 | ||
| 003 | DE-627 | ||
| 005 | 20240229163130.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/jclinpath-2020-206957 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1308.xml |
| 035 | |a (DE-627)NLM313126712 | ||
| 035 | |a (NLM)32737190 | ||
| 035 | |a (PII)jclinpath-2020-206957 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Malapelle, Umberto |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Predictive molecular pathology in the time of coronavirus disease (COVID-19) in Europe |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 27.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a AIMS: Lung cancer predictive biomarker testing is essential to select advanced-stage patients for targeted treatments and should be carried out without delays even during health emergencies, such as the coronavirus (COVID-19) outbreak | ||
| 520 | |a METHODS: Fifteen molecular laboratories from seven different European countries compared 4 weeks of national lockdown to a corresponding period in 2019, in terms of tissue and/or plasma-based molecular test workload, analytical platforms adopted, number of cases undergoing programmed death-ligand1 (PD-L1) expression assessment and DNA-based molecular tests turnaround time | ||
| 520 | |a RESULTS: In most laboratories (80.0%), tissue-based molecular test workload was reduced. In 40.0% of laboratories (6/15), the decrease was >25%, and in one, reduction was as high as 80.0%. In this instance, a concomitant increase in liquid biopsy was reported (60.0%). Remarkably, in 33.3% of the laboratories, real-time PCR (RT-PCR)-based methodologies increased, whereas highly multiplexing assays approaches decreased. Most laboratories (88.9%) did not report significant variations in PD-L1 volume testing | ||
| 520 | |a CONCLUSIONS: The workload of molecular testing for patients with advanced-stage lung cancer during the lockdown showed little variations. Local strategies to overcome health emergency-related issues included the preference for RT-PCR tissue-based testing methodologies and, occasionally, for liquid biopsy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a biomarkers | |
| 650 | 4 | |a lung neoplasms | |
| 650 | 4 | |a molecular | |
| 650 | 4 | |a molecular biology | |
| 650 | 4 | |a pathology | |
| 650 | 4 | |a tumour | |
| 700 | 1 | |a Pisapia, Pasquale |e verfasserin |4 aut | |
| 700 | 1 | |a Iaccarino, Antonino |e verfasserin |4 aut | |
| 700 | 1 | |a Barberis, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Bellevicine, Claudio |e verfasserin |4 aut | |
| 700 | 1 | |a Brunnström, Hans |e verfasserin |4 aut | |
| 700 | 1 | |a de Biase, Dario |e verfasserin |4 aut | |
| 700 | 1 | |a De Maglio, Giovanna |e verfasserin |4 aut | |
| 700 | 1 | |a Ericson Lindquist, Kajsa |e verfasserin |4 aut | |
| 700 | 1 | |a Fassan, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Fontanini, Gabriella |e verfasserin |4 aut | |
| 700 | 1 | |a Gruppioni, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Hofman, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Merkelbach-Bruse, Sabine |e verfasserin |4 aut | |
| 700 | 1 | |a Molina Vila, Miguel A |e verfasserin |4 aut | |
| 700 | 1 | |a Pujals, Anaïs |e verfasserin |4 aut | |
| 700 | 1 | |a Rapa, Ida |e verfasserin |4 aut | |
| 700 | 1 | |a Righi, Luisella |e verfasserin |4 aut | |
| 700 | 1 | |a Rosell, Rafael |e verfasserin |4 aut | |
| 700 | 1 | |a Schildgen, Oliver |e verfasserin |4 aut | |
| 700 | 1 | |a Schildgen, Verena |e verfasserin |4 aut | |
| 700 | 1 | |a Schmitt, Fernando C |e verfasserin |4 aut | |
| 700 | 1 | |a Tallini, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Vander Borght, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Vigliar, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Volante, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Wagener-Ryczek, Svenja |e verfasserin |4 aut | |
| 700 | 1 | |a Weynand, Birgit |e verfasserin |4 aut | |
| 700 | 1 | |a Troncone, Giancarlo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical pathology |d 1947 |g (2020) vom: 31. Juli |w (DE-627)NLM000031372 |x 1472-4146 |7 nnns |
| 773 | 1 | 8 | |g year:2020 |g day:31 |g month:07 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/jclinpath-2020-206957 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2020 |b 31 |c 07 | ||